4//SEC Filing
Gerngross Tillman U. 4
Accession 0001209191-21-051296
CIK 0001832038other
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 9:23 PM ET
Size
12.8 KB
Accession
0001209191-21-051296
Insider Transaction Report
Form 4
Gerngross Tillman U.
DirectorChief Executive Officer10% Owner
Transactions
- Conversion
Series A Preferred Stock
2021-08-10−5,000,000→ 0 total(indirect: See Footnote)→ Common Stock (25,000,000 underlying) - Conversion
Series B Preferred Stock
2021-08-10−44,076→ 0 total(indirect: See Footnote)→ Common Stock (220,380 underlying) - Conversion
Common Stock
2021-08-10+25,860,700→ 27,845,995 total(indirect: See Footnote) - Conversion
Series C Preferred Stock
2021-08-10−128,064→ 0 total(indirect: See Footnote)→ Common Stock (640,320 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.
- [F2]These shares are held by Adimab, LLC (the "LLC"). The Reporting Person is an officer and member of the Board of Directors of the LLC and, as such, may be deemed to have shared voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Adagio Therapeutics, Inc.
CIK 0001832038
Entity typeother
Related Parties
1- filerCIK 0001722061
Filing Metadata
- Form type
- 4
- Filed
- Aug 11, 8:00 PM ET
- Accepted
- Aug 12, 9:23 PM ET
- Size
- 12.8 KB